107
Archived articleThis is an archived article from 2025 - please note that any content within the article may be out of date.

Daily Stock Market Report (Tue 19th August 2025) - TRB, APN, NANO, IWG, CORD, BSIF

Good morning! Let's see what's in store today.

Today's Agenda is complete - it seems that the City is on the beach this week! Wrapping it up there, thanks everyone.


Spreadsheet accompanying this report: link (last updated to: 1st August).


Companies Reporting

Name (Mkt Cap)RNSSummaryOur view (Author)

BHP (LON:BHP) (£102bn)

FY2025 Results Announcement

Met prod’n guidance. $26bn adj. EBITDA, $10.2bn adj. profit. FY26 copper prod’n to remain strong.

International Workplace (LON:IWG) (£2.3bn)

Half-year results

SP -17%
Reiterates FY25 guidance: adj. EBITDA $525-565m, but likely towards lower end of the range.
H1 adj EBITDA +6% to $262m. H1 pre-tax profit -62.5% to $12m.
AMBER/RED (Roland)
This serviced office group is making progress at developing its capital-light Managed & Franchised division. However, fee income from this side of the business remains low compared to its portfolio of owned and leased properties, where growth is more sluggish.
I’m also a little concerned that net lease liabilities of >$1bn suggest some properties may currently be loss making. While today’s outlook statement was not technically a profit warning, I think a cautious view is justified given the relatively weak outlook for this year. Brokers are markedly more bullish for FY26, however, so this could be worth watching.

Cordiant Digital Infrastructure (LON:CORD) (£764m)

Amendment to Investment Management Agreement

Investment managers are no longer required to reinvest 10% of their fee into CORD.AMBER (Graham) [no section below]
The requirement to reinvest 10% of the management fee back into CORD shares doesn’t strike me as particularly onerous. However, the Board says that there is “strong existing alignment”, given that the investment manager and its Chairman already own 2% of the company. Additionally, they note that the management fee reduces if market cap is less than NAV - this further strengthens alignment. These are good arguments, but I still find it a little strange to remove the 10% reinvestment requirement at this time. NAV per share was 129.6p as of March 2025, and a 2.25p dividend has been paid since then. Even after recent gains, the share price today is only 99.53p! Surely the investment manager and its Chairman should be only too happy to add more shares to their existing positions at this price?

Bluefield Solar Income Fund (LON:BSIF) (£571m)

Q4 update

NAV -4.26% for quarter, NAV total return -2.47%. Lower power demand expectations.AMBER/GREEN (Roland) [no section below]
Falling forward power prices for the years through to 2030 are putting pressure on NAV for many renewable generators at the moment. Together with the Q3 dividend payment, this headwind accounted for the majority of the fall in NAV during the three months to 30 June.
More positively, solar generation was 8.4% above forecasts for the period – unsurprisingly. But despite the company’s name, Bluefield also has exposure to wind assets which have underperformed this year, meaning total generation was only 4.4% above forecast.
Management have left full-year dividend guidance unchanged today and say the payout should be covered by earnings, after scheduled debt repayments. That seems broadly reassuring to me. Gearing of 45% of gross asset value is also fairly typical for this sector.
This isn’t a renewable IT I follow closely and I would want to understand more about its debt and asset profile before forming a strong conviction. However, based on today’s update, my initial view is that the discount to NAV and 9% dividend yield represent reasonable value, with the potential for an attractive income.

Applied Nutrition (LON:APN) (£328m)

FY25 Trading Update & FY26 Outlook

SP +9%
FY25 ahead of exps, with rev +c.24%, adj EBITDA +c.19%. FY26 also to be ahead of exps.
AMBER (Graham)
Pleased to see this following through after a strong H1 and beating its full-year guidance provided at IPO. As this is still a recent listing, I'm maintaining caution, but it is starting to look interesting. The CEO and CFO still have large stakes and while the StockRank doesn't yet perceive much value, I think an argument could be made that it's not overly expensive at this level. Even after today's gains, the shares remain below their 150p IPO price. The shares are now slightly above their 140p IPO price.

Tribal (LON:TRB) (£101m)

Interim results

Rev +2.3%, adj EBITDA +18.4% to £8.3m. Recent wins mean FY25 results to be ahead of exps.

Update 15.45 (RH): Singer updated forecasts:
FY25E EPS: 4.2p (prev. 3.7p)
FY26E EPS: 4.4p (prev. 4.0p)
AMBER/GREEN (Roland)
Today’s results look positive to me, with organic growth and improved profitability.
A combination of £4m in recent contract wins and the continuation of some legacy contracts into H2 appear to have prompted an upgraded FY25 outlook statement today. Sadly we are not given any financial guidance and do not have access to broker notes, so can’t be sure of the financial impact of today’s upgrade. My guess is that it might erase most of the expected deficit in adjusted EPS for FY25 vs FY24, leaving Tribal on a P/E of c.13x.
Update 15.45 (RH): Tribal's PR people have kindly sent me a new Singer note with updated forecasts. See opposite for details. This FY25 estimate leaves the stock on a FY25 P/E of 13 at 56p.
Given current momentum, I’m happy to maintain our moderately positive view at this level.

Nanoco (LON:NANO) (£26m)

FY Trading Update & Founder retirement

FY rev £7.6m, ahead of exps. Adj EBITDA also “moderately ahead”. Year-end cash £14m.AMBER/RED (Graham)
Staying cautious on this despite the company beating expectations for the year. There are no forecasts for the year ahead, and meanwhile a live process is ongoing with the company seeking acquirers and new investors. The investment thesis here is unclear to me, and so I think a healthy dose of caution remains sensible. The founder is sailing into retirement - at least his 4% holding will not create a major overhang, if he decides to exit the shareholder register

Conygar Investment Co (LON:CIC) (£18m)

Sale of Virgin Active gym at The Island Quarter

Sale price of £6.75m is below Mar ‘25 valuation of £7.5m. Cash will be used to partly repay £12m loan.

Cambridge Nutritional Sciences (LON:CNSL) (£8.3m)

Final Results

Rev -15%, PBT +310% to £1.6m. Cash £4.9m. Improved production yields have cut scrap by 41%.



Graham's Section

Applied Nutrition (LON:APN)

Up 9% to 142.9p (£357m) - FY25 Trading Update - Graham - AMBER

Applied Nutrition plc, a leading sports nutrition, health and wellness brand, today announces an update on trading for the financial year ending 31 July 20251 and outlook for the financial year ending 31 July 20264.

This is a recent IPO (October 2024).

I was AMBER/RED on an initial glance, due to the £370m market cap which seemed excessive.

When nearly £100m was taken off the market cap, I turned neutral.

We have now had an ahead of expectations update, so perhaps I might need to upgrade my stance further?

Driven by strong second-half trading (approximately £60m of revenue), Group revenue is expected to be ahead of market expectations, with revenue up 24% year-on-year to approximately £107 million (FY24: £86 million) and adjusted EBITDA up approximately 19% year-on-year (FY24: £26m).

The company helpfully confirms that prior expectations were for revenues of £100m, so if my maths is holding up we have a beat of 7% against that figure.

Today’s announcement doesn’t explicitly say that the EBITDA result is ahead of expectations. But I think it is ahead: adj. EBITDA will be around £31m. It’s a less than 10% beat, so today’s rise in the APN share price of about 9% makes sense.

How did they do it: “continued delivery of the Group’s multi-pillar, global growth strategy”.

Cash: consistent with better-than-expected profitability, year-end net cash is £18.5m, vs. expectations of £16.6m.

Outlook: revenue for FY26 is now expected to be ahead of expectations (these expectations being £112.4m).

CEO comment:

"We are proud to report that we have exceeded the guidance we gave at our IPO, with our first full-year results expected to come in ahead of market expectations. Our focus and ambition remain as strong as ever - in delivering for our shareholders, customers and team - and we are excited about the opportunities we have in the pipeline for the year ahead."

Graham’s view

I’ve been a little sceptical of this Coleen Rooney-backed brand, seeing as it’s a recent IPO. This means we don’t yet have a sense of how it sets market expectations - will it habitually under-promise and over-deliver? Too soon to say.

It is clear now that the expectations set at IPO were too low.

There was already a hint that this was going to happen, when H1 revenues came in higher than expected, but the company chose not to raise full-year guidance at that time.

In future reporting periods, we can check to see if management remains cautious when it comes to setting expectations (a good thing, in my book!).

In Value terms, Stockopedia’s view hasn’t changed much. The ValueRank was only 16 last time I checked, and it’s currently 18.

AD_4nXcsYcWAtpIt_NNYxMhvJowKgd9lhNhtiwJyY4d9lJOJ4OPI5-QSQK3-iV4hhWsDjIpL3cpSijEVRrIP73ukntL49BS8klceBPFNGIVbQLuLftJ1av_sYGSpFWbircdEno_n0RrlGA?key=2yEohJW2hYREXnfGYtk76g

However, I note that the “Industry” used to benchmark valuation metrics is “Specialty Retailers”. This means it’s measured against the likes of NXT (I own), KGF, JD., BRBY (I own) and FRAS. Many - not all - of the retailers in this category have extensive brick-and-mortar operations and they should trade cheaply compared to brands sold online and via distributors.

I’ll round up the FY26 EPS forecast to 9.5p. At the latest price, that puts the shares on a P/E multiple of 15x.

It's worth noting that the CEO and CFO still own 39% of the company between them.

Their revenue capacity is said to be around £160m, thanks to a factory expansion that was completed last year.

I’m tempted to break my IPO rule, which says that I can’t get positive about a new IPO until two years have passed or the share price has fallen 50%.

The IPO price here was 150p 140p (latest price: 143p), and it has still been listed for less than a year.

I’m going to respect the rule and stay neutral on this for the time being. But I’d be happy to keep this on a watchlist - it’s beginning to look interesting to me.

AD_4nXdWKKdL7Q4hr-K-B-d9RIKqtYOsizJaXTu2l9iaK3TmRB2IhRaD24yPQTSum7vG2BrJh6vNcQ056emrtCuwlsKjAXuDpz4RSLvDRUJDIJ0kb2_IZn2Zt6vlBE2pu-cnEF0uDJeg1g?key=2yEohJW2hYREXnfGYtk76g


Nanoco (LON:NANO)

Up 2% to 13.45p (£26m) - Full Year Trading Update & Director Retirement - Graham - AMBER/RED

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, today provides the following year end

I’m not a scientist and so I can’t pretend to understand what this technology is all about.

Products and markets listed on Nanoco’s website include: iris recognition/face recognition, driver assistance systems, robotic vision, TV/phone displays, and optical security tagging.

I’ve been AMBER/RED on the stock, most recently last November, due to cash burn.

A large shareholder - Milkwood - tried to shake up the board and keep cash inside the business, but that effort failed.

According to interim results published in April, the strategy remains to “divest the Group’s trading business”. They were “actively engaged with a number of potential acquirers”.

Today’s update brings the following news:

  • FY July 25 revenues £7.6m, exceeding forecasts (£7.2m).

  • Underlying adjusted EBITDA “moderately ahead of expectations”.

Cash reduces to £14m, “above market expectations due to lower than anticipated litigation costs and positive working capital variances”.

The monthly cash cost base is £0.5m.

Estimates: thanks to Cavendish for a fresh update this morning. The EBITDA forecast for the year just finished is £1.5m (previous: £1.3m).

Their new EBIT number for the year is marginally positive (£0.18m), having previously been marginally negative (-£0.02m).

However, it’s important to note that there are no forecasts for the current year (FY July 2026).

CEO comment:

"This has been an important year for Nanoco during which our business development team has been fully focused on enhancing Nanoco's profile and maximising our organic growth prospects. Consequently, we have a number of promising, ongoing discussions with companies across several industry segments regarding future product developments, some of which are in new areas for the Group. In tandem, we remain in discussions with multiple parties as we assess our strategic options to maximise value for shareholders, and look forward to updating shareholders in due course."

Director retirement: the founder and Chief Technology Officer retires and is replaced internally by a “Director of Technology” (a non-Board position). The retiring founder owns 4% of the shares - not a huge overhang if he was inclined to sell them.

Graham’s view

I’m inclined to stay AMBER/RED on this.

Given that the company is engaged with “multiple parties”, looking for acquirers, there is always the possibility that we’ll wake up some morning to fantastic buyout news for shareholders here.

But the divestment strategy must bring downsides. Surely the company’s employees and joint venture partners would prefer a firm outcome, to help them plan for the future?

Hopefully we’ll get a conclusion to this process before too long.

The £14m cash balance does account for over half of the current market cap. And the company is apparently operating around breakeven, which should help to limit cash burn.

If I was more comfortable with the science behind the company, perhaps I could take a more positive view. But overall, the investment thesis here is unclear to me. FY25 revenues are lower than FY24 revenues, a fact not mentioned in today’s full-year update. Perhaps I could be educated to a more bullish stance, but a healthy dose of caution seems sensible.

Stockopedia categorises it as a Momentum Trap:

AD_4nXeEq6EL6qOLnwfehTXKJ2xn5vq6v7AG7JxUxp70lhXwHW_JEtUiLB_Au0kTJ2K3DbWGNEPG7b5MUie1vmpLCiJCCMu0SemkRTkrrrpJSQUpmnjdoqXIl6ojj96Deqc9iSorXvGG?key=2yEohJW2hYREXnfGYtk76g




Roland's Section

Tribal (LON:TRB)

Up 24% to 58p (£126m) - Roland - Interim Results - AMBER/GREEN

Tribal (AIM: TRB), a leading provider of software and services to the international education market, is pleased to announce its interim results for the six months ended 30 June 2025.

When Mark covered Tribal’s full-year results in March, he took an AMBER/GREEN view, commenting that he could see “little reason” for the share price drop on that day.

Today’s half-year results suggest he may have been correct. Tribal shares have risen by 30% since then (prior to today’s gains) and the outlook statement suggests full-year results are now likely to be ahead of expectations, thanks mainly to £4m of recent contract wins.

AD_4nXfQugQrYCj86DS_U6u90NIH0jciLESl2FD1SZS_D6oe7iV2QG0RlQ43crCcPeT8BQAyHY7YMvCj0wgvpleXesgEvkyRxrgJgmh0D0l9W91GyLTTg7SHYHilm5_2--rHdWoewINF?key=2yEohJW2hYREXnfGYtk76g

H1: rising recurring revenue

These results show solid progress with growth in recurring revenue and improved margins:

  • Revenue up 2.3% to £45.3m at constant currency

  • Adjusted EBITDA up 18.4% to £8.3m

  • Pre-tax profit up 451.7% to £5.6m

  • Earnings per share up 322.9% to 1.8p

  • Net debt reduced by 61% to £3.9m

Sharp-eyed readers will notice the big discrepancy between the 18% increase in adjusted EBITDA and the 452% increase in pre-tax profit.

The main reason for this appears to be a big reduction in adjusting items compared to the first half of last year – these fell from £3.4m to £0.6m:

AD_4nXeqFYLT32V9756l4fEl9MiTgIP1P5kO6zmJIlJ2J4uueO_F0wpKLAP4ZsKpw3TIejFo8CZyTt5_EDyhWuzqRsStWgUStPFCs2aLPwT-VH3jrkVHQciSUbKdrSTEjkd7ac-U6nbQxA?key=2yEohJW2hYREXnfGYtk76g

In fairness, most of the H1 24 items do look like genuine exceptionals. So perhaps we can hope for cleaner accounts from Tribal in the future.

This also means that today’s statutory pre-tax profit figure of £5.6m is a fairly reasonable measure of ‘real’ profit, in my opinion.

Adding back finance costs gives an operating profit of £6.0m – equivalent to a respectable 13.2% operating margin (FY24: 7.7%).

Cash generation is weighted to the second half of the year to reflect the timing of many licence renewals. But I don’t see anything much to worry about in the accounts – Tribal appears to be comfortably profitable and cash generative.

Trading commentary: Tribal is working through the loss of a large legacy contract that’s expected to have a £3m adverse impact on EBITDA. The company is also migrating customers away from perpetual licences and onto annual subscriptions, which can also have an adverse effect on short-term revenue.

Given these headwinds, today’s growth seems very encouraging to me. Gains appear to have been driven by new customer wins and upsells with existing customers, driving Annual Recurring Revenue (ARR) up by 5.5% to £59.9m:

Student Information Systems (SIS): revenue up 4.2% to £36.1m, with 9.6% growth in “core revenues” offsetting “the expected decline in legacy contracts”.

54 customers are now signed up for the Higher Education Full-Service subscription model. Cloud migration revenues rose by 16.5% as customers migrate or upsell from older services.

Three major software upgrades were released, “supporting customer transition to the cloud and entry into new markets”.

Etio (education services): revenue fell by 4.5% to £9.2m “following the successful completion of two major projects”. This was partially offset by the start of the Attendance Monitors project.

This division is said to have performed well “within a challenging market”.

Outlook: Tribal has won £4m of new business since the end of the half year, including two “significant new SIS wins” with London South Bank University and Durham University. On a year-to-date basis, these wins mean ARR has now risen by 12.7% to £64.0m since the start of the year.

Certain legacy contracts are also now expected to continue into H2, further underpinning FY25 expectations.

Together, these factors seem to have driven today’s upgrade to expectations:

the Board is increasingly positive about delivering FY25 results ahead of current market expectations.

Sadly, no upgraded broker notes are available to us today, so we’re left guessing at the potential impact on profit guidance for this year. Today’s c.25% share price rise suggests to me the market is pricing in a fairly significant upgrade. Tribal’s adjusted earnings had previously been expected to fall from 4.7p to 3.9p per share this year. I wonder if today’s updated guidance might be sufficient to neutralise this and improve the FY outlook to a flat result?

-

Update 15.45 (RH): Tribal's PR people have kindly sent me a new Singer note with updated earnings forecasts. Many thanks. These suggest adjusted earnings for the year are still expected to be lower than the 4.7p reported in FY25, but do suggest improved momentum with upgraded to both FY25 and FY26:

  • FY25E EPS: 4.2p (+8% vs 3.9p previously)
  • FY26E EPS: 4.4p (+10% vs 4.0p previously)

At the time of writing, Tribal shares re trading at 56p, putting the stock on a FY25E P/E of 13.3, falling to 12.7 in FY26.

-

Broker forecasts have shown a flat trend until recently -- I expect this picture to improve following today’s updated forecasts:

AD_4nXeh4VU3KEnaSLWl534mQ65lYR3CHjPauyfbWmGTolqkq9x2OvpfgY9KqHyED9ijFNc0qGdLLSqGNumcF_xBlSBovXXP4_gfwyDoZlkj_O38Gc_u8FGxlyFkA46s0LtD8FTpy-Hk3g?key=2yEohJW2hYREXnfGYtk76g

Roland’s view

I note that small cap specialist Harwood Capital recently increased its Tribal shareholding quite significantly. It looks like Harwood also shared Mark’s benign view of the March FY24 results:

AD_4nXegVESDFTCDMvppUvYtuRFzdguxhAs7mgKUl9sDEwL_ZLI34qilYz2gO75BmCM4G0h98S6MXLIoJWxBkDBNfDAf-1B66tXFy8zsSkXN6tsIHFMs5qUwl_JvKENdKP8fH7iK-hKt2Q?key=2yEohJW2hYREXnfGYtk76g

I’m encouraged by today’s news, but frustrated that we have no visibility of new earnings expectations – with the share price up c.25% but no guidance available, it’s difficult for us as private investors to form an informed view without building our own financial model of the business.

I’d also note that at a statutory level, at least, Tribal’s quality metrics are quite average. However, I’d expect to see some improvement on these metrics when these interim figures are digested by Stocko’s algorithms:

AD_4nXdvLfFaSAXcnr1KYQhTcqYghOI5FZD6dkHwYAP0ZQTp8oknd8wmc-CjAKOiFrLE6hugUq_VD6emR7K2EcI4muRQyjd55NoFrWjTfkRGPyKL1qk_DJpJRPwMezJOnjeeA7SXOBET?key=2yEohJW2hYREXnfGYtk76g

I haven’t looked at Tribal before but do not see anything to dislike on this initial inspection. If my earnings guesswork is in the right ballpark, then I think the shares could also remain reasonably valued even after this morning’s gains.

I’m going to leave Mark’s AMBER/GREEN view unchanged today.


International Workplace (LON:IWG)

Down 17% to 189p (£1.9bn) - Roland - Interim Results - AMBER/RED

This serviced office / shared workspace provider operates in 120 countries, but is best known in the UK as the operator of Regus offices. It also has a number of other brands – see here and says it offers solutions “from one hour to five years”.

IWG claims to be by far the largest operator in this sector:

AD_4nXe1UpTgSBDnhSSXC2Ou2iioRf3R8Vf_GOloVSduo-EyY7MLUUv8N5BBDx8MY5gAHJivSlu5Iv6C2PyZ2mHEcwJ2aqIeHwzjePX8gs5q0481yjghkDJLjisE4Ol6VrpBgrvFvJzgrQ?key=2yEohJW2hYREXnfGYtk76g

This isn’t a business we cover very often, but today’s half-year results have prompted a double-digit share price drop despite the company reiterating its full-year guidance – so I thought they might be worth a look.

AD_4nXfKfBWgiPrqNjNR_66tc1xbx9RxomvC7tztqXs1aGnDtnTA8YvMf8T4XLNPgzWHZrr9Z6cJP1dWDOSwFmLnfoxVYinqm9fTdh8_uuyiZ14mQTbswXfVpC9P_-ky1BtuwPRx67NtuQ?key=2yEohJW2hYREXnfGYtk76g

H1 results summary: today’s half-year figures look pretty mixed to me – some numbers are up, but some are down.

Here’s a selection of key metrics:

  • System-wide revenue up 2% to $2,162m

  • Group revenue down 1.1% to $1,850m

  • Adjusted EBITDA up 6.1% to $262m

  • Operating profit flat at $68m

  • Pre-tax profit down 62.5% to $12m

  • Adjusted earnings up 22% to 1.1c per share

Understanding these results requires a quick assessment of IWG’s balance sheet. The company is targeting capital-light growth, but is burdened with a big legacy of more capital-intensive owned and leased properties:

  • Right-of-use assets (leases): $5.5bn

  • Property and equipment: $800m

It looks like some of these leased properties may currently be loss making, too. My sums show total lease liabilities of $6.5m, giving net lease liabilities of -$1.1bn.

In addition to all of these leases, IWG has net debt of $754m.

In simple terms, lease and finance costs broadly account for the whole of the reduction from adjusted EBITDA of $262m to pre-tax profit of just $12m.

To correlate this, my sums suggest free cash flow for the half year of $31m.

Company-owned vs franchise growth: in fairness, IWG does seem to be making an effort to move away from its historical strategy of leasing the properties it occupies and then sub-letting them to tenants.

The company has a Managed & Franchised division where IWG provides the management, branding and marketing for commercial landlords. This appears to be the main area of growth in the business. The number of centres open rose by 262 to 1,365 during H1, with fee income (gross profit) climbing 43% to $50m.

However, this part of the business is still small compared to the sluggish Company-owned division, where 2,895 centres generated an 8% increase in gross profit to $375m.

Digital & Professional Services: the other capital-light element of the business is the group’s services business. This contributed $98m of gross profit in H1, an underlying reduction of 10% despite a 6% increase in underlying revenue. I haven’t looked into this in any detail to understand what these services are.

Outlook: IWG has reiterated its FY25 guidance today, but it looks to me like expectations have been nudged downwards slightly all the same (my emphasis):

Adjusted EBITDA of $525m-$565m, but likely to be towards the lower end of the range due to further investment in Managed and Franchise segment growth

Today’s H1 EBITDA figure of $262m equates to $524m annualised. I don’t know if there’s much seasonality to this business, but this result does seem to suggest a figure towards the lower end of the range unless growth improves in H2.

I’d argue that EBITDA is not very meaningful here, given the extensive lease costs. But consensus forecasts prior to today suggested adjusted earnings of just 7.3c per share this year. That puts the stock on a FY25E P/E of 34 after this morning’s drop.

Roland’s view

IWG appears to be trying to pursue the same kind of capital-light success as hotel operator Intercontinental Hotels (LON:IHG). It may well succeed over time, but my initial impression is that it could be some time yet before the benefits of the Managed & Franchised operations outweigh the drag from the group’s portfolio of owned and leased properties.

A $1bn net lease liability also suggests to me that IWG may be struggling to make a profit from some of its company-owned properties.

To be fair, this business suffered painful disruption during the pandemic. Market conditions now seem to be normalising, with a growing number of companies wanting their workers back in the office for the majority of the time. That could be positive for IWG.

Another positive, perhaps, is that CEO Mark Dixon appears to be a 25% shareholder, giving him a strong incentive to create value for equity holders:

AD_4nXcig_9gtmBPyGQqci2GaTBWgTFXNxQ7nMuenn0jdMQ000MtS2yVjgGfSrSybk4sf-xTE4fUk4woFQ2XY5p__k42nRZBxz7UE6ymuT7fhtIDZ-Wdcw7wcq4TwQ6U05WPBElxcgwvNA?key=2yEohJW2hYREXnfGYtk76g

Brokers have been relatively positive on this stock until recently, but FY25 consensus was already falling before today’s update. I suspect a further reduction may be likely following today’s results:

AD_4nXeopY4wmXJw4VAyel460AyX4AbmLhXSs2alAS5hgBmL7Ws3nJNJ9DReKYsz3I8lcSMH-JDnj9KM4dSjZtcLYdEnROpwN-55oHAQLamOD2kJDi0y-5g4Sby8wQNWXkjLvdfE3OJ-?key=2yEohJW2hYREXnfGYtk76g

Prior expectations are for a strong recovery in growth next year. That could provide support for a stronger valuation.

Personally, I’d be wary about jumping in following today’s results. Our research has found that companies often underperform following a profit warning – and while today’s results were not officially a downgrade, the outlook was not exactly bullish, either. I’m going to take a cautious view here and go with AMBER/RED.

Disclaimer

This is not financial advice. Our content is intended to be used and must be used for information and education purposes only. Please read our disclaimer and terms and conditions to understand our obligations.

23 comments


Avatar for HHR

Applied Nutrition (LON:APN)

Each month I analyse all London IPOs and like Graham I am automatically sceptical of all of them. However when I looked at apn it stood out among the recent crop (although that’s probably more of a negative reflection on them than a positive stance on apn itself).

Personally, I thought the forward PE of 15 at IPO was suspiciously low for a company that had grown profitably from nothing in 2014, without using debt and with only one capital injection in 2021.

The involvement of Peter Cowgill and Andy Bell appealed to my heart but my head reminded me it is surprising how often good entrepreneurs make bad investors.

My brief research revealed that the fitness industry is prone to controversial advertising and sales practices although I was encouraged that apn itself seemed to be clean in this regard. Further digging revealed that although the company had a market leading position in the UK and Europe, it’s initial foray into the imortant US market had been unsuccessful.

That initial failure in the US market, together with the apparently low IPO valuation and lack of institutional enthusiasm for the IPO lead me to hold off an investment and watch.

The interims revealed a significant dent to margin despite good sales growth. Although the poor margin comparator was explained convincingly, the US update was vague and I was happy to be still watching.

This weeks FY IMS looks encouraging. The dent to EBITDA margin in H1 has been recovered for the FY – it will be interesting to see if that margin performance is confirmed by pre-tax profits in the results themselves. If it is, and the finals give a positive update on the US, and the shareprice breaks above 150p then that will be a good time to invest I think.

1
Avatar for Ted Striker

Tribal (LON:TRB) up over 10% on ahead of expectations, however the stockrank is only 69.  Given that the stockrank is likely to move soon on momentum and quality, leading to an improvement on overall stockrank, where does that leave us on Ed's ahead of expectations system?

I ask, because I am currently benefitting from accidently pressing the button on Zotefoams (LON:ZTF) before realising that the stockrank was below 75, it is now up to 82. I'm currently 16% up  

7
Avatar for sevenccc

Have a look in the morning Ted. Tribal (LON:TRB) might have crossed the magic line by then.

2
Avatar for Charles10

For those interested in Warpaint London (LON:W7L) JPM disclose this am that they have reduced their holding from just under 10% to c 5.2%

21
Avatar for The Boon Fund

Applied Nutrition (LON:APN) and THG (LON:THG) are both in the sweet spot of a macro trend : more and more people taking up Strength and Weight training at the gym. Cardio is out, Balance (yoga, etc) is out of fashion.

A key component of Strength and Weight training is consuming protein. Hence why you see in the supermarkets, loads of new products with proteins - protein drinks, high protein ready meals, etc.

The easiest way to get protein are protein shakes. These are the most popular products from APN and THG's MyProtein brand.

So I'm not surprised that APN has released above expectations growth. THG did the same a few weeks ago, saying MyProtein growth rates are rapidly accelerating.

If you believe in this tailwind of growth, then paying 15x PE for APN is cheap.

My pick, and the one I hold at the moment, is THG - even better bagging potential, given its debt situation and investor loathing.

10
Avatar for Spider1234

So many shares looking so weak currently, been a good run past few months but could this be a peak?

Only been investing a few years, September to November not usually great months. Hope I'm wrong, just the fear in me!!

3
Avatar for The Phoenix

Actually the last three months historically are pretty good but September generally dire and August not great.

23b29090-a4c4-4a7f-98b4-af5e8cd23811.png

15
Avatar for Spider1234

I stand corrected!

3
Avatar for Epitychia

Are they US numbers? May and July are usually weak in UK. 

1
Avatar for The Phoenix

I'm not sure to be honest equally if say they are based on something like MSCI World it could be the figures shown are based on the dollar so exchange rates could skew the average shown in the UK also.

0
Avatar for mbarnard

When Applied Nutrition (LON:APN) was initially listed the eps figures shown on Stockopedia were incorrect. They showed eps of 0.94p rather than the correct figure of 9.4p.  It has since been corrected though the analyst concensus shows a decline in eps from 841p a share since January 2025. I believe this accounts for the low value rank. Perhaps you could check to see if the value rank on Stockopedia is correct

3
Avatar for sharw

Tribal (LON:TRB) up 30% at the moment. Harwood built up from 10% to 15% during July. You can find their comments here including "only on AIM do you wonder what divorce proceedings are going to do!" (referring to the Maginns and Jenzabar).

1
Avatar for The Phoenix

Be great if you had a chance to have a look at Nanoco (LON:NANO) Graham I used to hold in early trading days of buying loss making story stocks, its the classic example of a story stock with an in theory product changing technology that ticks all boxes but never gets any real orders.

Somehow though like a lot of other story stocks it keeps going for decades getting away multiple share raises at lower and lower prices.

In my next life I'm hoping to come back as an Aim company director with tales to tell of a massive oil find in Mongolia or such like.

I'm guessing Nano has enough cash for another 18 months to two years before another raise is needed I do wonder what research some of these fund managers do as their always seems someone ready to put some money in all be it normally at a 30-40% discount to the last market price close.

20
Avatar for Mark Carter

NANO Ah, that was a stock I bought and sold a long time ago. At a loss, obviously. It was an education to me in why not to buy story stocks.

14
Avatar for The Phoenix

Same here Mark along with a few other howlers in my early days.

3
Avatar for Wimbledonsprinter

It is a while since I looked at Nanoco (LON:NANO) . IIRC the “revenue” in this and future years is related to the accounting treatment of selling licences to Samsung a while ago as part of the litigation settlement.   The cash has long since been received.   This “revenue” is a non-cash item.    I would only look at the cash-flow statement and the balance sheet and ignore the P/L statement.  


5
Avatar for Epitychia

The Phoenix: 

It is easy to see why some private investors might fall for story stocks. Promising untold riches just around the corner. 

I think someone did some research that the small cap shares who had the most attention on bulletin boards were by far the worst performers. Dull mature companies that are temporarily marked down not only provide much better returns but are also low risk. 

I have watched AFC Energy (LON:AFC) over the last decade, it is possibly the worst performer on the stock market over that time. They have actually done worse than companies that have gone bust because they continue making losses by raising capital every 18 months or so.  

What surprises me is that story stocks seem to be kept afloat by institutional investors. It is mainly fund managers who are subscribing for each round of fund raising. 

If any reader can explain how or why the so called 'smart money' is throwing away their customers' cash, please let me know. 

17
Avatar for SheriffJEB

There used to be an understanding that if you helped a broker earn a corporate finance fee by tipping a bit of cash into a flakey fund raise they were struggling with, you would be favourably treated when there was a juicy IPO or discounted secondary offering having to be heavily scaled back.

8
Avatar for grout123

Success has a hundred fathers and failure is an orphan 

5
Avatar for Silver Moon

Ha ha! Mongolia, shades of Petro Matad (LON:MATD)  of which I'm a long-time sufferer.

0
Avatar for Graham Neary

Posting up now, The Phoenix! Thanks for the request.

0
Avatar for The Phoenix

Much appreciated Graham as I say no position in it but would be great to get your thoughts on a classic story stock example, these days I generally don't touch anything loss making, aim listed or sub £250 market cap (last one mainly liquidity reasons).

3
Avatar for doctor dave

Georgia Capital (LON:CGEO) Buyback *and cancellation* declared. Good to see clarity about the bought back shares. Too often left open and therefore of uncertain value...

9
Get the free newsletter